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Case presentations
Patient I. An 8-year-old boy was hospitalized for pneumonia and had
a grand mal seizure that was unresponsive to anticonvulsant therapy.
He was transferred to the Children's Hospital in Cincinnati in a
postictal state. The blood pressure was 136/80 mm Hg. Uncentrifuged
urine contained Ito 3 red blood cells per high-power field and 2+ to 4+
protein. The BUN was 13 mg/dl. He recovered from the seizure and
was discharged. Two weeks later generalized edema, hematuria, and
massive proteinuria were found during a followup outpatient visit. The
BUN was 32 mgldl and the serum C3 level was 42 mg/dl (lower limit of
normal, 86 mg/dl).
The patient was readmitted for a renal biopsy, which revealed
membranoproliferative glomerulonephritis, type II. He was treated
with prednisone, 60 mg/day in divided doses; 12 days later, cyclophos-
phamide was added. An initial dose of 4.4 mg/kg of cyclophosphamide
was used for 8 days, after which the dose was increased to 6.2 mg/kg.
The drug was discontinued after 16 days because of leukopenia. During
this interval, the C3 level rose to normal. The patient was discharged 50
days after admission; prednisone, 60 mg every other morning, was
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prescribed. He remained well for one month, after which he again
developed pneumonia accompanied by gross hematuria.
He was readmitted (then 4 months after the apparent onset of his
illness) for a second renal biopsy. The biopsy findings were unchanged.
The prednisone was reduced to 30 mg/day in divided doses, and
azathioprine, 3.5 mg/kg, was added. After one week, the latter was
increased to 5.3 mg/kg, but was discontinued after 30 days because of
leukopenia. Hypertension worsened and required medication. On dis-
charge 1.5 months later, pitting edema of the ankles was still present,
proteinuria was 4+, and the urine sediment contained a moderate
amount of occult blood. The serum albumin was 2.5 g/dl, and the BUN
was 17 mg/dl. The prednisone dosage was changed to 30mg once daily.
While the patient remained home, the edema disappeared and he began
to feel better. By 11 months after the onset of his illness, proteinuria had
diminished to I +, urinary occult blood was either absent or negligible,
and the serum albumin concentration had risen to 3.6 g/dl. Large doses
of antihypertensive medications, however, were still required. The dose
of prednisone was reduced to 20 mg once daily.
The patient was readmitted for the fourth time 3 months later (14
months after the onset of symptoms) because of right lower lobe
pneumonia and otitis media; gross hematuria and proteinuria also were
present. Protein excretion was 2.8 g/24 hours. He continued to receive
prednisone, 20 mg once daily. After the infection subsided, proteinuria
diminished to a trace; the serum albumin level, which had fallen to 2.4
g/dl during the hospitalization, rose to 3.3 g/dl. The prednisone was
discontinued 2 months later to facilitate control of hypertension. Over
the next 6 months, proteinuria gradually increased to 4+, the serum
albumin level fell to 1.5 g/dl, and massive edema developed. Despite
supportive therapy, total renal failure ensued and, 4 years after clinical
onset of his disease, he underwent renal transplantation.
He enjoyed good health in the posttransplant period, but within 2
years the disease recurred in the transplanted kidney. A second
transplant was performed 3 years after the first. Once again the disease
recurred and a third transplant was performed 6 years after the first.
Ten years later, 20 years after the onset of membranoproliferative
glomerulonephritis, he again has massive proteinuria, hematuria, and
edema; he is presumed to have a third recurrence of the disease.
Patient 2. A 6-year-old boy was admitted to a hospital because of
intermittent vomiting and weight loss over 3 months. The urine was
found to contain a large number of red blood cells and proteinuria was
4+. Minimal edema was present on admission but became more severe.
He was treated with fiuprednisolone, 6mg 4 times daily for 18 days, but
the edema worsened. Nine weeks after admission the blood pressure
rose to 210/140 mm Hg and he became comatose.
He was transferred to the Children's Hospital in Cincinnati with
anasarca. The BUN was 24 mg/dl; the total serum protein, 3.6 g/dl; and
the serum albumin, 1.5 g/dl. Proteinuria was 4+. A renal biopsy yielded
an inadequate amount of tissue for diagnosis and was not immediately
repeated because of the patient's precarious clinical state. He was
treated with prednisone, 2 mg/kg/day, in divided doses; after 5 days,
cyclophosphamide, 4 mg/kg, was added. Over the next 15 days, the
dose of cyclophosphamide was slowly increased to 8 mg/kg. This dose
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was continued for an additional 5 days before the medication was
stopped; leukopenia did not occur but a duodenal ulcer developed. On
the 57th hospital day, the prednisone was tapered and subsequently
stopped, and cyclophosphamide, 2 mg/kg, was restarted. The dose of
cyclophosphamide again was gradually increased over 27 days, but
vomiting developed at a dose level of 4 mg/kg and the drug was
discontinued.
The patient showed steady clinical improvement. By 2 months after
admission to the hospital, edema had disappeared; by 4 months after
admission, the serum albumin level was 3.5 gIdl and the BUN was 16
mg/dl. Occult blood disappeared from the urine and proteinuria dimin-
ished to 21-. Renal biopsy 6 months after admission yielded 13
glomeruli, 4 of which were sclerotic. There were no crescents and no
periglomerular fibrosis, and tubular atrophy was slight to moderate.
The glomeruli were proliferative but not markedly so. Electron micro-
scopic findings established a diagnosis of type-IL membranoprolifera-
Live glomerulonephritis.
For the next 4.5 years, 1-1- to 2+ proteinuria persisted without
symptoms, hematuria, or abnormal serum chemical values. Nearly 5
years after his first admission, however, microhematuria reappeared
and proteinuria increased to 4+. Another renal biopsy revealed little
change: 4 of 20 glomeruli were sclerotic. Nephrotic syndrome devel-
oped soon after the biopsy and prednisone was restarted in a dose of 1.6
mg/kg/day in divided doses. After 12 days, the same dose was given
once every other morning, but the nephrotic syndrome persisted.
Several months later the serum creatinine concentration began to rise
and 22 months later a renal transplant was performed. He remains well
15 years later. Renal function is normal and the urine contains only a
trace of occult blood.
DiscussIon
DR. CLARK D. WEST (Director, Division of Nephrology,
Children's Hospital Medical Center; Professor of Pediatrics,
University of Cincinnati College of Medicine, Cincinnati,
Ohio): Membranoproliferative glomerulonephritis (MPGN) is a
chronic nephritis that occurs most commonly in children and
young adults. Based on differences in the glomerular ultrastruc-
ture, three forms of idiopathic MPGN are recognized. In type-I
MPGN, the glomerular deposits are subendothelial and the
glomerular basement membrane is intact. In type-LI MPGN,
also known as dense-deposit disease, the glomerular basement
membrane is thickened and the electron density of the lamina
densa is greatly increased. Type-Ill MPGN is characterized by
both subendothelial and subepithelial deposits: basement mem-
brane-like material formed on the surface of these deposits
eventually produces a glomerular basement membrane that has
a fenestrated and duplicated appearance. The glomerular scle-
rosis that leads to renal failure in all three types appears to be
caused by deposition of immune complexes in the glomeruli.
These complexes coalesce in the mesangium to form discrete
deposits that produce inflammation, severe mesangial cell pro-
liferation and, eventually, glomerular sclerosis. Conditions in
which immune complexes containing a defined antigen persist
over long periods produce a glomerular morphology identical to
that in idiopathic MPGN [1—3]. It thus seems reasonable to
postulate that idiopathic MPGN also is the consequence of
prolonged formation of immune complexes. Moreover, immune
complexes detected by Clq binding as well as by other means
are found in the circulation of patients with this disease [4, 51.
The antigen or antigens contained in these complexes have not
been identified, however, and there is no way of judging the
nephritogenicity of the complexes measured by these methods.
Thus the factors that cause otherwise healthy individuals to
deposit complexes in their glomeruli are not clear. Only in a
general way can we say that MPGN is a chronic, immune-
complex disease; intimate details of its pathogenesis remain
obscure. This lack of knowledge obviously hampers the devel-
opment of an effective therapeutic regimen.
In the 1960s, immunosuppression with cytotoxic drugs, often
combined with prednisone, was the popular approach to the
therapy of MPGN and other glomerulonephritides. The two
patients under discussion here were first seen during that era.
Both had type-Il MPGN and were treated with relatively short,
intensive courses of cyclophosphamide; Patient 1 also had a
course of azathioprine. Patient I received a low dose of
prednisone daily for 16 months, and Patient 2 was given
prednisone daily in high dosage for nearly 2 months. One
cannot determine from the course of events in these 2 patients
whether the diminution of proteinuria and loss of hypoalbumin-
emia and hematuria was the result of the corticosteroid, of the
cytotoxic drugs, or of neither; some patients with type-li
MPGN do have a benign course [61. In any event, nephrotic
syndrome recurred in both patients, in one a few months and in
the other 4.5 years after prednisone was discontinued.
Because cytotoxic drugs seemed ineffective in this disease in
our hands and, as subsequently reported, in those of others [7—
9], the treatment that evolved at this center employed large
doses of prednisone administered on alternate days. Since
January 1966, we have treated 51 patients with MPGN with this
regimen, and an analysis of its effects on clinical course,
glomerular morphology, and renal survival has been reported
[10]. Before summarizing the results of that analysis, however,
I will comment on other approaches to the treatment of this
disease, and I will emphasize some of the difficulties in assess-
ing their effects. A variety of therapies have been tried. In
addition to using immunosuppressive agents to reduce antibody
formation, some clinicians have tried to prevent glomerular
fibrin deposition by administering anticoagulants [11—141, to
reduce platelet-mediated injury by administering antiplatelet
agents [11, 14, 15], and to allay the inflammatory effect of the
immune deposits using nonsteroidal [16] and steroidal [13, 17—
19] antiinflammatory agents. Many investigators have used
several of these therapeutic approaches simultaneously.
Judging the effectiveness of a given regimen for MPGN is
often difficult. A chronic disease, MPGN is rapidly progressive
in some; in most, slowly progressive; and in a few, relatively
benign. The course is not characterized by frequent, well-
defined relapses that can be targeted for short-term tests of
therapy as, for example, is the case in systemic lupus erythe-
matosus. The natural history of MPGN is such that end-stage
renal disease occurs in approximately 50% of patients 10 years
after presentation [7, 20—221. If prevention of end-stage renal
disease is the end-point of a therapeutic trial, long-term obser-
vations are needed: this difficulty can be avoided by careful
experimental design,
If therapy is initiated before renal function begins to decline,
effectiveness can be gauged by assessing certain markers, such
as improvement in glomerular morphology, resolution of uri-
nary abnormalities, and disappearance of hypoalbuminemia. In
using these markers, however, several caveats must be heeded.
With respect to glomerular morphology, our observations have
indicated that in the untreated child with MPGN, glomerular
sclerosis develops at a rate averaging 3,5% of the glomeruli per
year. In our experience, this rate of sclerosis may not be
immediately altered by therapy [17, 181, and improvement in
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glomerular morphology may best be equated with reduced
proliferation of functional glomeruli. In our experience, glomer-
ular proliferation may diminish markedly as the number of
sclerotic glomeruli increases. In judging the resolution of uri-
nary abnormalities as a measure of effectiveness, one must bear
in mind that spontaneous resolution of the urinary abnormality
is common in this disease [20, 21, 23, 24]. Spontaneous remis-
sions usually are transient, however [20], and most frequently
occur in patients with focal and segmental lesions [21, 25]. A
rigorous judgment about the effectiveness of any regimen
therefore requires that the trial be confined to patients with
diffuse glomerular proliferation (to minimize variability in se-
verity of the disease) and that remissions persist at least while
the regimen is being used. Patients with focal and segmental
proliferation should not be included in the study.
If a therapeutic regimen is instituted after renal function has
started to decline, the rate of change in glomerular filtration rate
and serum creatinine level can be used to judge effectiveness
[14, 15]. In using this criterion, one must bear in mind that
glomerular sclerosis in glomerulonephritis may well result ini-
tially from an immunologic insult and, later on, from a nonim-
munologic process [26—29]. The relative contributions of immu-
nologic and nonimmunologic insults to glomerular sclerosis at a
given point in time is difficult to assess. Certainly, if filtration
rate approaches 50% of normal, nonimmunologic injury is likely
to be a factor in further glomerular attrition, and it might be a
factor even before function deteriorates to this extent [27]. In
two of the controlled trials of therapy in MPGN [14, 15], a
number of patients with low glomerular filtration rates were
included. In the study by Donadio et al [15], some of the
patients at the the start of the treatment period had filtration
rates as low as 19 mL/min/l.73 M2, and the average GFR was
approximately 70 mllmin/1.73 M2. Zimmerman and colleagues
studied 6 patients for whom data for paired treatment and
placebo periods were available [14]. The serum creatinine levels
averaged 3.0 mg/dl at the start of the treatment period; two were
above 4.0 mg/dl. With functional deficits this severe in patients
with long-standing disease, nonimmunologic injury could have
been the principal cause of progressive deterioration of func-
tion. Thus, these regimens have been effective in slowing or
halting the nonimmunologic injury.
Our patients' characteristics and study design. We analyzed
the effectiveness of an alternate-day prednisone regimen in 45
patients with MPGN whose glomeruli showed diffuse prolifera-
tion and who presented at this center since January 1966 [10].
Six additional patients presenting during that time were exclud-
ed from the analysis because their glomeruli contained only
focal and segmental lesions, findings that presage a benign
course [21, 25]. The clinical course of the 45 patients with
diffuse proliferation is shown schematically in Figures 1 and 2.
For the purposes of presentation, I have considered the time at
which laboratory abnormalities (hematuria or proteinuria) were
first discovered as the clinical onset of the disease. It is obvious
that when the urinary abnormality is discovered by chance in
the asymptomatic patient, the true onset can antedate the
clinical onset by a considerable period. The course of the 25 in
whom the clinical onset was less than one year before the start
of treatment (minimal-delay group) is diagrammed in Figure 1,
and the course of the 20 patients whose onset was greater than
one year before the regimen was started (long-delay group)
Fig. 1. Course of MPGN in 25 children in whom the alternate-day
regimen was started within one year of clinical onset (minimal-delay
group). The alternate-day regimen started at zero time. Type of MPGN
is indicated by stippling. Closed circles indicate clinical onset; X, renal
biopsy; M, mechlorethamine; ESRD, end-stage renal disease. A trian-
gle indicates the point at which the patient was lost to followup. (From
Ref. 10.)
appears in Figure 2. The alternate-day regimen consisted of
prednisone, 2.0 to 2.5 mg/kg (maximum, 80 mg), as a single dose
on alternate days. The daily dose, in mg/kg body weight,
usually fell with time both because of reductions in the dose and
because most patients gained weight. The patients have been
followed for an average of 6.5 years since the start of this
regimen.
At the start of the alternate-day steroid regimen, 17% of the
patients had mild to moderate renal failure, defined as serum
creatinine levels from 1.6 to 3.0 mgldl. In the remainder,
creatinine concentration was 1.5 mg/dl. In 33%, the serum
albumin concentration was 2.5 g/dl, and in 38%, it ranged
between 2.6 and 3.7 gIdl. At the start of the regimen, 42% had
diastolic blood pressures that were >2 SD higher than the mean
for age, or they were receiving antihypertensive medications.
All had proteinuria, and 91% had either gross or microscopic
hematuria.
Immunosuppressive and platelet inhibitor therapy used with
the alternate-day regimen. The effect of the short course of
cyclophosphamide given to Patient 26 (Fig. 2) and of the course
of azathioprine given before the start of the alternate-day
regimen to Patient 36 (Fig. 2) could not be evaluated. As I have
noted, cytotoxic drugs used in this fashion are now thought to
be ineffective in this disease [7—9].
Because of our concern about the prognosis of this disease in
certain patients, we treated 11 of them with 3- or 4-day courses
of mechlorethamine (Figs. 1 and 2). We based this approach on
the success of this regimen in reversing relapses in certain
patients with mild SLE [30]. The drug was given intravenously,
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Fig. 3. Values for the reciprocal of the serum creatinine concentration
versus years after start of the alternate-day regimen for Patient 31.
Dipyridamole and aspirin were given in a one-dose per day regimen
with the alternate-day regimen, as indicated. The regression lines were
calculated by the method of least squares.
FIg. 2. Course of MPGN in 20 children in whom the alternate-day
regimen was started more than one year after clinical onset (long-delay
group). A, azathioprine; C, cyclophosphamide. Other abbreviations
and symbols as in Fig. 1. (From Ref. 10.)
0.1 mg!kg, usually on successive days. Three patients (Patients
6, 22, and 32) received the drug because of persistence of, or
recurrence of, hypocomplementemia; 6 (Patients 8, II, 16, 21,
29, 37) because of an elevated serum creatinine level when first
seen or a rising level as they were observed; and 2 (Patients 12
and 43) because of a relapse of nephrotic syndrome. Improve-
ment after the therapeutic course was seen in 3 patients
(Patients 8, 21, 29) with an elevated serum creatinine level when
first seen and in the 2 with a relapse of nephrotic syndrome. All
5 of these patients also were receiving prednisone in high doses
on alternate days. The condition of 3 (Patients 6, 22, 32) did not
change, the renal function of one (Patient 6) continued to
deteriorate slowly, and 2 (Patients 11 and 37) developed ESRD
within one year. Thus S improved, 3 were unchanged, and 3
deteriorated.
Six patients (Patients 11,31,32,33,37, 38) received dipyrida-
mole-aspirin in a single-dose-per-day regimen in addition to the
alternate-day prednisone regimen; 3 of these patients (11, 32,
37) also received mechlorethamine. The dose of dipyridamole
was 75 to 100mg once daily, and of aspirin, 0.32 to 1,0 g once
daily. The courses were of 11 to 42 months duration. Renal
function in 2 of the 6 was consistently normal both during the 32
to 40 months the medication was given and during the 50 to 60
months after it was discontinued. Patient 32 had a renal biopsy
after 40 months of the dipyridamole-aspirin regimen that
showed no significant change from the first biopsy. Two of the
patients (Patients 11 and 37) developed end-stage renal disease
while receiving dipyridamole and aspirin, and in 2 others
(Patients 31 and 33) renal function diminished. In fact, in the
latter 2, the rate of deterioration of function was greater while
the dipyridamole-aspirin regimen was being given than after it
was discontinued. The data for one of these patients are given in
Figure 3. In summary, function remained normal in 2 and
deteriorated in 4.
It is difficult to conclude from these observations that either
the mechlorethamine or the dipyridamole-aspirin regimens fa-
vorably altered the natural history of the disease. The failure to
demonstrate improvement with dipyridamole might reflect the
low dose employed. When used with more apparent success by
others [14, 15], dipyridamole was given three or four times daily
in daily doses three to four times those employed in the present
study.
Actuarial renal survival. Survival of renal function sufficient
to maintain life without dialysis in the patients in the present
study is contrasted in Figure 4 with such survival in 105 patients
with MPGN of all types reported by Habib et al [20]. Renal
survival of those in our study has been calculated separately for
all patients with diffuse proliferative lesions (n =45) and for the
patients who received neither mechlorethamine nor the dipyri-
damole-aspirin regimen (n 31). The similar survival of the two
groups supports the conclusion that, as employed in this study,
these two therapeutic modalities are neither antagonistic nor
synergistic to the effect of the alternate-day prednisone
regimen.
Survival of the patients in our study is significantly better
than that in the series of Habib et al [20], as indicated by the
vertical lines in Figure 4. In their study, 69 patients were not
treated, and the remaining 36 received relatively short courses
of immunosuppressive drugs, prednisone, and antimalarial
agents in various combinations. Presumably, some of their
patients had focal and segmental lesions, which presage a good
prognosis [311. The clinical and laboratory characteristics of our
patients at the start of the regimen were similar to those of the
patients of Habib et al at clinical onset (Table I). The average
age was similar, as was the percentage of crescents in the initial
biopsy. Azotemia and a nephrotie syndrome were somewhat
less frequent in our series, but hypertension was more frequent.
The renal survival in series of patients reported from England
[7], Boston [32], Toronto [21], and Vancouver 122] was similar
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Alt. day (n = 45) 454442 3935 3226 21 20 19 13 11 9 8 8 8
Alt, day In = 31) A 31 30 2926 2522 18 14 13 13 10 9 8 7 7 7
Habib et al 0 10591 82 78 59 5338 28 25 20 13 7 6 2 1 1
Fig. 4. Actuarial renal survival of patients with MPGN plotted against
years after clinical onset. For the patients in the present series, survival
is given separately for all patients (open triangles, n = 45) and for the
patients in the series who did not receive the dipyridamole-aspirin or
mechlorethamine regimens (closed triangles, n = 31). For contrast,
survival of patients reported by Habib et al [20] is also given (open
squares, n = 105). The vertical line represents the 95% confidence
intervals for the 45 patients in the present series and the 105 patients of
Habib et al at the ninth year. (From Ref. 10.)
to that of the patients in the Habib study [20]. At variance with
these results are findings by Watson and colleagues: survival in
a subgroup of 9 patients with focal and segmental lesions was
100% [21].
In our series, end-stage disease developed in 2 of 25 (8%) of
those in the "minimal-delay" group and in 5 of 20 (25%) of
those in the "long-delay" group. Of the 2 in the former group
whose renal function failed, one (Patient 11) had rapidly pro-
gressive disease that was unresponsive to the alternate-day
regimen, and the other (Patient 14) confessed at the time of
transplantation to having been noncompliant with the regimen
over long periods. The 5 patients who developed end-stage
renal disease in the latter group were among those with the
greatest delay before the regimen was started; the onset of their
disease was 2.5 to 8 years (average 5.5 years) before the start of
the regimen.
Comparison of the "minimal-delay" and the "long-delay"
groups. Separation of the patients into two groups, depending
on the time the alternate-day regimen was started, has given
insight into the efficacy of the regimen in MPGN. For the
insight to be meaningful, however, disease in the two groups
Present study at start of
alternate-day regimen
Habib et al at
clinical onset
Number 45 105
Males 56% 43%
Type of MPGN
1 40% 72%
II 18% 28%
II! 42% —
Mean age, years 9.7 10
Azotemia 26%b 31%
Hypertension 42% 25%
Nephrotic syndrome 47%c 67%d
Hematuria 91% 88%
Crescents in first biopsy 15% 15%
Minimal-d
group
n=25
clay Long-del
group
n=20
ay
Percentage No. Percentage No.
Type! 45 9 36 9
Type!! 20 4 16 4
Type III 35 7 48 12
Characteristics at clinical onset
Edema 24 6 20 4
Gross hematuria 20 5 20 4
Nonspecific illness 12 3 15 3
Chance hematuria and/or
proteinuria 40 10 35 7
Unknown 4 1 10 2
Characteristics at time
regimen started
Serum creatinine >1.5 g/dl 20 5 15 3
Serum albumin
s2.5 g/dl 36 9 35 7
2.6—3.8g/dl 36 9 40 8
Hypertension present 44 11 40 8
Age at clinical onset in the minimal-delay group was 10.4 years and
in the long-delay group, 8.6 years. The difference was not significant.
should be similar in severity as assessed by clinical and
laboratory data. Such data are shown for the two groups in
Table 2. Approximately the same percentage of patients in both
groups presented with edema; this finding has been reported by
others to presage a poor prognosis [7, 20]. Similarly, the
frequency with which proteinuria and hematuria were discov-
ered serendipitously in an apparently healthy child was equal.
When the therapeutic regimen started, the two groups also were
similar in the frequency of nephrotic syndrome, azotemia, and
hypertension.
The extent of the renal histologic abnormalities in the two
groups can be compared in Table 3. The data allow assessment
of differences in glomerular proliferation, numbers of sclerotic
glomeruli, and extent of tubular atrophy. To quantify glomeru-
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Table 1. Clinical and laboratory abnormalities of patients of present
study compared with those of Habib et al [20]
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Age at clinical onset.
b Serum creatinine concentration  1.4 mg/dl.
Serum albumin concentration <3.0 g/dl.
d Defined as association of proteinuria, >50 mg/kg/day; serum pro-
teins, <6 g/dl; serum albumin, <3 g/dl.
Table 2. Comparison of the minimal-delay and long-delay groups with
respect to type of MPGN and characteristics of the diseases
2 4 6 8 10 12 14
Years after clinical onset
16
Table 3. Comparison of the first renal biopsies in the minimal- and long-delay groups
Estimate of open Prominence of Glomerular Tubular
n capillary lumens mesangial matrix sclerosis atrophy
Percent Max 100 Percent Max 100
65.5 16.6 17.9 21.5
69.0 15.2 30.9 25.1
44.8 28.0
44.5 23,3
Table 4. Comparison of glomerular morphology in initial biopsies at start of alternate-day regimen, in second biopsies, and in third biopsies
Estimate of open Prominence of Glomerular Tubular
capillary lumens mesangial matrix sclerosis atrophy
Percentage Max = 100 Percentage Max = 100
For 31 patients with paired initial
and second biopsies'
Initial biopsy 41 24" 68 IS 6.2 8.9 22 23
Second biopsy 68 21 53 16 16.1 16.1 36 25
P value <0.001 <0.001 <0.01 ns
For 12 patients who had third
biopsies
Second biopsy 65 19 57 21 13 10 34 16
Third biopsy 77 25 46 17 13 15 37 21
P value ns ns ns ns
Average interval between initial and second biopsies was 34 months; the range was 23—69 months.
"Mean I SD,
Average interval between second and third biopsies was 52 months; the range was 29—96 months.
lar proliferation, estimates have been made of the number of
open capillary lumens, expressed as the percentage of total
capillary lumens, and of prominence of the mesangial matrix as
seen with the periodic acid Schiff (PAS) stain. The biopsies in
the two groups were evaluated "blindly" and did not differ
significantly in glomerular proliferation even though those in
the long-delay group were, on the average, 3 years from onset,
as opposed (by definition) to the recent onset of those in the
minimal-delay group. As might be predicted, there was more
glomerular sclerosis and tubular atrophy in the long-delay
group, but only the difference in glomerular sclerosis was
significant (Table 3).
The data give no evidence that, without intervention, the
natural course of the disease in the patients starting the regimen
promptly would have been fundamentally different from that of
the group referred after they had had their disease for some
time.
flct of the prednisone regimen on parameters of disease
progression. In Table 4, characteristics of the biopsy before the
start of the regimen can be compared with those of the second
biopsy obtained, on the average, 32 months after the start of the
regimen. Data for paired first and second biopsies were avail-
able on 31 of the 45 patients. The biopsies were assessed
without knowledge of the clinical status of the patient. The
estimated percentage of open capillary lumens was significantly
greater in the second biopsy, whereas the prominence of the
mesangial matrix by PAS stain was significantly less. On the
other hand, the number of sclerotic glomeruli increased signifi-
cantly during the 32 months; the extent of tubular atrophy also
increased but the increase was not significant. Over the 32-
month period, the rate of glomerular attrition averaged 3.7% per
year.
Separate calculations for the minimal-delay and the long-
delay groups showed an equal increase in the number of open
capillary lumens and equal diminution in prominence of the
mesangial matrix. There was also no significant difference
between the two groups in the extent of increase in sclerotic
glomeruli or of increase in tubular atrophy.
The serum ereatinine rose in 12 patients, 7 of whom devel-
oped end-stage renal disease. In the remaining 33 patients, the
serum creatinine level either remained less than 1.5 mg/dl or, in
those with an initially elevated level, fell to less than 1.5 mg/dl
while the regimen was being employed.
A rising serum creatinine level and hypertension occurred
more frequently in the long-delay group. In the minimal-delay
group, renal function deteriorated in 20%, and in the long-delay
group, in 35%. The frequency of hypertension in the minimal-
delay group remained at 44%, but in the long-delay group it
increased from 40% to 75%.
Of the 19 patients who were hypertensive when the regimen
started, 5 no longer require antihypertensive therapy, and 14
remain hypertensive; 4 additional patients became hypertensive
while receiving the regimen. Uncontrollable hypertension did
not occur.
Serum albumin. All 12 of the 45 patients who had a normal
serum albumin level at the start of the regimen had a normal
level when last seen. In addition, 21 patients who had a low
serum albumin prior to therapy had a normal level when last
examined. Thus, only 27% of the group as a whole was
hypoalbuminemic on the most recent examination, whereas
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Fig. 5. Cumulative percentage of patients initially hypoalbuminemic
achieving a normal serum albumin level after the start of the alternate-
day regimen. Data for patients starting the regimen with less than one
year delay are indicated by the solid circles; data for patients starting
with greater than one year delay are noted by open circles. (From Ref.
10.)
hypoalbuminemia was present in 72% when the regimen was
initiated.
Improvement in serum albumin levels is shown for the two
groups in Figure 5. Of those who were initially hypoalbumine-
mic, serial serum albumin levels were available for 18 in the
minimal-delay group and for 13 in the long-delay group. Con-
trasting the cumulative percentage of those whose serum albu-
min became normal after the start of the regimen indicates that
the serum albumin levels more quickly and more frequently
came into the normal range in those starting the regimen with
little delay.
Proteinuria. Proteinuria, recognized by semi-quantitative
measurement in all 45 patients when the regimen was initiated,
disappeared in 12 (27%). As Figure 6 illustrates, proteinuria
disappeared earlier and more frequently in those starting the
regimen with little delay. Of those in the minimal-delay group,
24% became free of proteinuria within 2 years of institution of
the regimen, whereas in the long-delay group, only 5% did so
within this interval.
Hematuria. Hematuria was present in 91% of the patients (41
of 45) at the start of the regimen. Excluding the 7 who
developed end-stage renal disease, hematuria disappeared in 28
(82%) of the 34 remaining patients. The cumulative percentage
of patients without hematuria was no different in the minimal-
and the long-delay groups (Fig. 7).
Twenty-seven percent of the patients, when last examined,
were in complete remission. Such complete remissions are not
40
30
20
<1 yeardelay. 25 21 20 17 15115 12 1211b 9 7 6 6 4 4 J 21
>1 year delay C' 2020 17 17 17116 15 15L13 13 12 11 10 10 7j5J
70
0,
C
0)
0
j50
40
CO
C
0,
0
20
0)
>
Cs
10
E
0
0
Months after start of regimen
Fig. 6. Cumulative percentage of patients without proteinuria after start
of the alternate-day regimen. Symbols as in Fig. 5. (From Ref. 10.)
uncommon in the natural history of this disease. Indeed,
remissions occurred in 10 of 33 patients reported by Watson et
al (30%), but 9 of 33 patients in their study (27%) had mild focal
and segmental lesions [21]; as noted earlier, we excluded this
histopathologic subgroup from the present study. Kim and
coworkers reported that, of 65 patients with type-I MPGN, the
urinalysis became normal in 5 (8%) [23]. Of the patients studied
by Habib and colleagues, remission occurred in 20 of 105 (19%),
but 70% of these patients subsequently relapsed [20]. In our
series, relapse was not observed in any of the patients who
achieved a complete remission while receiving the alternate-day
regimen.
Evidence that the alternate-day regimen alters the natural
history of MPGN. In addition to the favorable effect of the
regimen on renal survival (Fig. 4) and on glomerular morpholo-
gy (Table 4), evidence that it alters the progressive nature of the
disease is provided by a detailed analysis of the courses of the
patients in the minimal- and the long-delay groups.
First, the greater frequency with which those patients who
started the regimen with little delay became free of proteinuria
(Fig. 6) and corrected their hypoalbuminemia (Fig. 5)suggests
that the regimen can favorably influence the fundamental
mechanism of the disease. In a chronic progressive disease that
produces renal scarring, one would predict that if a regimen is
effective, it would be maximally therapeutic if started soon after
onset.
Second, the value of the regimen can be assessed by a
comparison of the status of the 20 patients in the long-delay
group at the time they started the regimen with their status
several years later. While receiving the regimen for an average
of 8 years, 4 became free of proteinuria, and 7 corrected their
hypoalbuminemia. None became hypoalbuminemic after the
regimen started. Admittedly, the regimen failed to prevent end-
stage renal disease in 5 patients. These patients had had their
disease for an average of at least 5.5 years by the time the
regimen was started. Given the poor prognosis associated with
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Table 5. Characteristics of disease and glomerular and tubular morphology at times represented by points A, B, and C in Figure 8
Point A Point B
P
value Point C
p
value
Clinical and laboratory characteristics
Hematuria present 90% (18/20) 48% (12/25) .003
Proteinuria present 100% (20/20) 76% (19/25) .015
Hypoalbuminemia present 75% (15/20) 32% (8/25) .004
Serum creatinine >1.5 mg/dl 15% (3/20) 12% (3/25) ns
Hypertension present 40% (8/20) 44% (11/25) ns
Glomerular morphology
Number 19 18
Avg. open capillary lumens 44% 71% 0.01
Avg. mesangial matrix prominence 69 51 0.01
Avg. sclerotic glomeruli 11.4% 13.9% as
Avg. tubular atrophy 31 30 ns
U The significance of the differences at Points A and B is essentially the same if patients receiving the dipyridamole-aspirin regimen or courses of
mechiorethamine are excluded. With their exclusion, n 13 at Point A and n = IS at Point B.
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Fig. 7. Cumulative percentage of patients without microhematuria after
start of the alternate-day regimen. Symbols as in Fig. 5. (From Ref. 10.)
the nephrotic syndrome [7, 20], however, the frequency with
which serum albumin levels normalized in patients who had had
their disease for an average of 2.5 years at the time the regimen
was started suggests that the regimen has a favorable effect.
Third, the effect of the regimen on the underlying disease
process can be assessed by comparing the status of the long-
and minimal-delay groups 42 months after onset. This compari-
son is illustrated in Figure 8. At point A, the characteristics of
the disease will be those of patients who have not received the
alternate-day regimen and are, on the average, 42 months from
clinical onset. These characteristics can be compared with
those of patients in the minimal-delay group who, at point B,
are also on the average 42 months from onset but who have
been receiving the alternate-day regimen for the previous 38
months. As indicated in Table 5, hematuria, proteinuria, and
hypoalbuminemia were significantly less frequent in those
receiving the regimen (at point B). On the other hand, the
—60 —40 —20 0 20 40 60
Time, months
Fig. 8. Djfferences in timing of the start of the alternate-day regimen in
the long-delay and minimal-delay groups. Asterisks indicate approxi-
mate time of first renal biopsy. The clinical characteristics of the disease
at points A and B and the renal biopsy assessments at points A and C
are compared in Table 5. (From Ref. 10.)
60 regimen did not alter the frequency of an elevated serum
creatinine level or of hypertension.
Fourth, analysis of this type also can provide insight into the
effect of the regimen on glomerular morphology. At point C in
Figure 8, 18 of the patients in the minimal-delay group were an
average of 33 months from onset and had been receiving the
alternate-day regimen for an average of 30 months. As shown in
Table 5, their biopsies revealed an average of 71% open
capillary lumens, significantly greater than the mean of 44%
observed in biopsies from 19 patients in the long-delay group at
point A. The patients at point A had manifested their disease for
an avenge of 42 months and during that time had not been
receiving the alternate-day regimen. The prominence of PAS-
positive material in the mesangium also was significantly less in
those receiving the regimen. On the other hand, the annual rate
of increase of sclerotic glomenili in the patients receiving the
regimen was greater (5% versus 3.5%) but the difference was
not significant. Tubular atrophy in the two groups was approxi-
mately the same.
In summary, on the assumption that the severity of disease in
the minimal- and long-delay groups was similar (Tables 2 and 3),
we conclude that the regimen described here causes hematuria
and proteinuria to disappear and that it normalizes serum
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albumin levels. Its effectiveness is greatest if started soon after
onset. This therapeutic approach also improves the morphology
of functioning glomeruli even in patients with long-standing
disease. On the other hand, our observations give no evidence
that early use of the regimen reduces the frequency of hyperten-
sion or azotemia in the first 2.5 to 3.5 years and even suggest
that the regimen might accelerate the rate of glomerular
sclerosis.
Effect of the alternate-day prednisone regimen on glomerular
sclerosis. How can we reconcile the continuing glomerular
attrition during the 2.5 or more years after starting the regimen
with the evident improvement in the serum albumin level, loss
of urinary abnormalities, and reduced glomerular proliferation
in the patients receiving the alternate-day regimen? Observa-
tions obtained from third biopsies yield evidence that glomeru-
lar sclerosis ceases after several years of the regimen. As noted
in Table 4, 12 patients had a third renal biopsy. In comparison
with the second biopsies, third biopsies showed no change on
average: over a mean interval of 52 months between the second
and third biopsies, there was virtually no change in the extent of
glomerular sclerosis and tubular atrophy. Although a slight
reduction in proliferation was found, as indicated by an increase
in the percentage of open capillary lumens and a reduction in
the PAS prominence of the mesangium, these changes were not
statistically significant.
From these observations, a hypothetical model can be con-
structed, beginning with the initiation of the regimen. At the
time the regimen starts, the glomeruli are injured to a variable
degree. The immunologic insult to some has been severe
enough to be irreversible, and these glomeruli are destined to
become sclerotic. The glomeruli in this cohort, indistinguish-
able at the time from those that will continue to function,
become nonfunctional over the next 2 to 3 years despite
institution of the regimen. Consequently, more sclerotic gb-
meruli are present in the second biopsy. The results of third
biopsies, however, suggest that the regimen prevents further
recruitment into this cohort and that the improvement in the
morphology of functioning gbomeruli usually seen in the second
biopsy persists. Thus, after 3 years, inflammation of immuno-
logic origin has been arrested, and gbomerular sclerosis by this
mechanism no longer continues to occur. If this hypothesis
about the lag in the effect of the regimen on the development of
glomerular scarring is correct, one would have another cogent
reason to institute the regimen promptly. An average increase
in sclerotic glomeruli of about 9% can be expected after 2.5
years of the regimen; of course, the percentage is likely to be
much greater in some, and much less in other, patients.
If glomerular sclerosis is arrested after 2 to 3 years of the
regimen, why has renal function in some patients continued to
deteriorate? As noted before, 7 patients developed end-stage
renal disease, and 4 others (Patients 1, 17, 31, and 33) have
slowly rising serum creatinine levels. In the latter patients, 14%
to 27% of the gbomeruli were sclerotic in the second biopsy;
subsequent to the second biopsy, serum creatinine levels con-
tinued to increase slowly. At the same time, the estimated
percentage of open capillary lumens in functioning glomeruli
increased by 10% to 50% over that in the initial biopsy. These
patients have not had third biopsies, but the rising serum
creatinine levels suggest that glomerular scarring is continuing
and, in view of the improvement in functioning glomeruli, it is
tempting to speculate that the progressive scarring is of nonim-
munologic origin. One can postulate that the initial glomerular
loss exceeded a certain critical number in these patients and
that glomerular injury subsequently occurred because of hyper-
filtration in the remaining functioning units. Patient 1 in our
series of 45 (Fig. 1) might illustrate this course of events. His
serum creatinine level increased from 1.6 to 2.0 mg/dl over 14
years. Sclerotic glomeruli were not present in the first biopsy
but glomerular inflammation was severe and, presumably as a
result of this inflammatory process, sclerotic glomeruli consti-
tuted 27% of the second biopsy. At the same time, open
capillary lumens in functional glomeruli increased from an
estimated 20% in the initial biopsy to 70% in the second. These
observations are consistent with the view that the immunologic
insult subsided some time before the second biopsy in this
patient and that the slow increase in the serum creatinine level
over the subsequent 10 years was the result of slow sclerosis of
gbomeruli by a nonimmunologic mechanism. Among the pa-
tients who developed end-stage renal disease, gbomerular loss
by a nonimmunologic mechanism appears to have been a
significant factor in 2 and could have been a contributing factor
in at least 3 others.
Relapses, noncompliance, and the effects of stopping the
alternate-day prednisone regimen. A relapse occurred in 2 of
the 45 patients in our series; one had MPGN II and the other,
MPGN III. In both, the relapse was preceded by a reduction in
prednisone dosage, and in both the reappearance of a nephrotic
syndrome heralded the deterioration,
Four patients had an episode of gross hematuria at the time
they were febrile with an infection 10 or more months after the
regimen was instituted. In 3 patients, the dose of prednisone in
the preceding months had been below the usual range, and the
fourth patient was known to be noncompliant. The episodes
occurred before microhematuria had disappeared, and renal
biopsies obtained immediately after the episodes in 2 patients
showed either no change or worsening of glomerular morpholo-
gy. From this limited experience, it is tempting to speculate that
an episode of gross hematuria 10 or more months after the start
of the regimen may indicate a continuing gbomerular inflamma-
tory reaction and reflect a suboptimal dose of prednisone.
Spitzer and Stitzel reported 2 patients with type-I MPGN
who improved clinically and by laboratory tests while receiving
the alternate-day regimen over periods of 4 and 6 years, but
who relapsed 30 and 60 days, respectively, after the regimen
was stopped [33]. Relapse was manifested by increased protein-
uria, return of hypocomplementemia, hypertension, and dimin-
ished creatinine clearance. Marked improvement occurred after
prednisone was restarted. A different sequence of events was
observed in 2 patients in the present series, both with type-I
MPGN (Patients 4 and 29). These patients initially were compli-
ant with the regimen, and after 42 and 60 months hematuria had
disappeared and proteinuria had greatly diminished. Renal
biopsies showed markedly improved glomerular morphology.
Although both these patients thereafter became noncompliant,
neither has suffered a relapse even though Patient 4 has been
noncompliant for 18 months and Patient 29 for 3 years. Warady
and coworkers purposely stopped the regimen in patients with
type-I disease without a relapse developing [34]. How patients
who will not relapse when the regimen is discontinued can be
distinguished from those who will [33] is not clear.
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Three other patients became noncompliant with the regimen
within months after it was started. Patient 14, noncompliant for
long periods, is one of the 2 in the minimal-delay group who
developed end-stage renal disease. Patient 43 has had progres-
sively diminishing renal function and increasingly severe hyper-
tension over a 9-year observation period. Patient 8, a member
of the minimal-delay group, has had less improvement in
glomerular morphology and laboratory abnormalities than
many other patients in this group have had.
In summary, the course of events in patients who had
relapses and who were noncompliant also was compatible with
the concept that alternate-day prednisone favorably alters the
natural history of the disease. In the 2 patients manifesting a
relapse with a nephrotic syndrome and in the 4 with episodes of
gross hematuria, the dose of prednisone had been below the
usual range. After the prednisone dose was increased, episodes
of gross hematuria did not recur and the nephrotic syndrome
slowly disappeared. Parenthetically, a dose below the usual
range did not always result in a relapse; in several the dose was
transiently low, and in others the regimen was discontinued for
short periods without causing obvious deterioration. Three
patients noncompliant with the regimen from the beginning
have deteriorated or have had relatively less improvement than
did comparable patients who were compliant. On the other
hand, our experience and that of others [34] indicates that in
some patients with type-I MPGN whose disease is in remission,
the regimen can be stopped without a relapse developing. In our
series, the regimen has not been purposely stopped in any
patient with MPGN II or III, but the experience with the
patients whose case summaries precede this discussion and
who are not included in this analysis suggests that discontinuing
the regimen in patients with type-H MPGN can result in
irreversible relapse,
Indicators of ongoing immunologic injury. An indicator of
the status of glomerular inflammatory reaction produced by
immune insult would be of great value in our understanding of
the natural history of the disease, and in our judging the effect of
and regulation of therapy. Laboratory measurements that might
be valuable in this regard are proteinuria, hypoalbuminemia,
hypocomplementemia, and hematuria. None, however, is ideal.
As I mentioned, proteinuria and hypoalbuminemia disap-
peared less frequently and were present longer after institution
of the regimen in the long-delay group. The most plausible
reason for this observation is that those in the long-delay group
had more renal scarring when the regimen started. In the
patients starting the regimen without delay, an average of 3.6%
of glomeruli were sclerotic, whereas in those in the long-delay
group, 11.4% were sclerotic (Table 3). It thus appears that
proteinuria and hypoalbuminemia in this disease can be the
result not only of immunologically mediated glomerular inflam-
mation but also of glomerular scarring. Supporting this conclu-
sion is the proteinuria frequently seen with the glomerular
sclerosis present in adults many years after an episode of acute
poststreptococcal glomerulonephritis [28] and with hyperfiltra-
tion injury in animals [26, 27]. Thus, proteinuria and hypoalbu-
minemia would not be reliable indicators of ongoing immuno-
logic injury.
Several points mitigate against the use of hypocomplemente-
mia as an index of disease activity. First, its applicability would
be limited to the fraction of the patients who are hypocomple-
mentemic when first examined. Second, hypocomplementemia
might depend on the presence of C3 nephritic factor, particular-
ly in those with type-Il MPGN, an autoantibody that has not
been shown to be nephritogenic. Third, hypocomplementemia
can disappear within a few months after the patient begins the
alternate-day regimen, particularly in those with type-I MPGN,
at a time when overall clinical evidence would indicate that the
disease is still active. Fourth, we have observed patients with
long-standing hypocomplementemia who have had improve-
ment in glomerular morphology. Representative of this is
Patient 20, whose course is illustrated in Figure 9. Clinical onset
at the age of 4 years was signaled by an episode of gross
hematuria accompanying a slight fever. This patient differed
from most patients in that the serum C3 and CS levels remained
very low after the alternate-day regimen was begun and,
because of the hypocomplementemia, the dose of prednisone
was increased above the usual range after 19 months of the
regimen. A repeat renal biopsy performed after 26 months of
hypocomplementemia showed improvement: the estimate of
open capillary lumens increased from 60% to 85%, and the
PAS-positive mesangial matrix was less prominent.
In Patient 45, with a similarly persistent hypocomplemente-
mia, improvement in the renal biopsy was observed after 2
years of a very low serum C3 level, and in Patient 32 improve-
ment occurred after 5 years of hypocomplementemia. The
reason for the long-standing hypocomplementemia in these
patients is not known. Currently, we do not consider persistent
hypocomplementemia to be evidence of ongoing immunologic
glomerular injury.
A number of points indicate that the immunologic insult is
subsiding and that healing is occurring when microhematuria
disappears. As noted in Figure 7, hematuria subsided as quickly
and with the same frequency in patients treated promptly as in
those treated after a greater-than-one-year delay. This finding
suggests that hematuria is not a consequence of scarring and
that it resolves as the glomerular inflammatory process sub-
sides. To gain more information about the latter point, we
correlated resolution of hematuria with changes in glomerular
morphology. In 9 of 10 patients, a renal biopsy performed 9 to
38 months (average, 18 months) after cessation of hematuria
showed diminished glomerular proliferation, The tenth patient,
biopsied 16 months after cessation of hematuria, manifested no
change in morphology. In 12 patients in whom biopsies were
performed before hematuria ceased, improvement had occurred
in 7 and there was no change in 5. Although these data are not
conclusive, they do provide some basis for assuming that the
clearing of hematuria is an indication that immunologic injury
and glomerular inflammation have subsided.
Complications of the alternate-day regimen. The major prob-
lem was growth deceleration. It was most severe in 9 boys but
also occurred in 6 girls. Growth in patients receiving the
regimen is plotted in Figure 10 for the 13 boys who were less
than 14 years of age when the regimen started. To foster
growth, the alternate-day regimen was reduced rapidly in
several patients. In Patient 44, reduction in dose was followed
by a relapse manifested by the nephrotic syndrome; in Patient
45, dose reduction was followed by an episode of gross hematu-
na, and a renal biospy showed worsening of glomerular mor-
phology. Thus in some patients, the choice appears to be
normal growth or active disease. Excessive obesity was gener-
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Fig. 9. Course of Patient 20. Serum concentration of C5 and C3, dose of
prednisone given on alternate days, and degree of proteinuria and
hematuria are graphed versus months after start of the alternate-day
regimen. The horizontal dashed lines indicate the lower limits of the
normal range for CS and C3, respectively; the shaded area illustrates the
usual range of the alternate-day dose of prednisone. This usual range is
the range of dose given to 6 of the children who weighed 20 to 34 kg at
the start of the regimen. Hence these children received less than the
maximum dose of 80 mg. They were patients with relatively severe
disease, and their dose of prednisone was not rapidly reduced. A renal
biopsy performed after 26 months of the alternate-day regimen showed
improvement despite continuing hypocomplementemia.
ally not a significant complication of the alternate-day regimen,
but most patients did experience an accelerated weight gain.
Eight patients have developed posterior subcapsular cata-
racts, all of which have been small and do not interfere with
vision. None of the patients have had osteoporosis or aseptic
necrosis of bone.
Severe hypertension necessitating discontinuation of the regi-
men has not occurred during the 290 patient years the present
patients have been followed using our regimen. In contrast,
among 23 patients in another series followed for fewer than 115
patient years, the regimen had to be discontinued in 6 patients
because of severe hypertension [351. In that series the dose of
prednisone was less than that in the present series.
Six of the women in the study have become pregnant; 4 had
uncomplicated deliveries of normal infants. One delivered a
Fig. 10. Growth curves for 13 boys who started the regimen when they
were less than 14 years old. The lines connect height at the start of the
regimen with height at the time of study or when last seen. (From Ref.
10.)
stillborn and a sixth had a spontaneous, first-trimester abortion.
The alternate-day regimen was continued in all during the
pregnancy.
Summary. In summary, analysis of our experience gives
evidence that high doses of prednisone administered on alter-
nate days to patients with all types of MPGN result in a loss of
proteinuria, restoration of the serum albumin level to normal,
and a reduction in mesangial proliferation. By contrast, in the
first 2 to 3 years of the treatment regimen, sclerotic glomeruli
and tubular atrophy increase and, correlated with these histo-
pathologic changes, the frequency of renal insufficiency and
hypertension remains unchanged. The continuation of glomeru-
lar sclerosis is self-limited, and I believe it reflects the slow
attrition of glomeruli suffering a severe immunologic insult
before the start of the regimen. The analysis indicates that
prompt institution of the regimen results in more frequent and
more rapid disappearance of proteinuria and hypoalbuminemia
and in more patients being spared glomerular loss leading to
nonimmunologic (that is, hyperfiltration) injury.
Questions and answers
DR. SATISH KUMAR (Renal Fellow, University of Chicago):
The first patient presented today had two relapses of protein-
uria associated with pneumonia. How frequent is this associa-
tion? Do you think the relapses were induced by the episodes of
pneumonitis?
DR. WEST: In many patients with glomerulonephritis, a
febrile episode produces gross hematuria and increased protein
excretion even though the glomerulonepbritis at the time is
Renal
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quiescent or healing. Such episodes occur in patients conva-
lescing from acute poststreptococcal glomerulonephritis or
Henoch-SchOnlein purpura; those with IgA nephropathy and
MPGN may also have such episodes. In MPGN, we have seen
an infected toe trigger such an episode. To answer your second
question, I would agree that a febrile episode often initiates a
relapse in patients with idiopathic nephrotic syndrome. In the
glomerulonephritides, however, increased urinary abnormali-
ties are often transient and subside as the febrile illness
subsides.
As a corollary, hitherto asymptomatic chronic glomerulone-
phritis may first be brought to the attention of the physician
because an infection triggers an acute nephritic episode. This
occurs particularly in type-I and -II MPGN. One rarely knows
the exact time of onset of disease in the patient with MPGN.
Without intervention, these patients can become asymptomatic
again. This is not always the case, however. It was not the case
with the first episode of pneumonitis in the first patient present-
ed today; he subsequently became edematous.
DR. JORDAN J. COHEN: Do febrile illnesses that are noninfec-
tious in nature have the same effects? If so, it might support the
notion that the effect on proteinuria is hemodynamically
mediated.
DR. WEST: I have not had the opportunity to observe the
response of a patient with a noninfectious febrile episode.
However, a reliable mother once told me that for several years
she could tell when her child, convalescing from Henoch-
SchOnlein purpura, was going to have a cold because 12 hours
before symptoms of the cold developed, his urine would turn
dark brown. Experiences like this have led me to believe that
the urinary abnormalities are the result of something more
subtle than hemodynamic changes.
DR. ADRIAN KATZ (Renal Section, Mitchell Hospital, Chica-
go): Could you comment about the treatment of adults with
membranoproliferative glomerulonephritis?
DR. WEST: I cannot comment on this with authority because I
have always cared only for children. With respect to the
alternate-day regimen, I believe the key consideration would be
how well adults tolerate a prednisone regimen of 80 mg every
other day; the Adult Collaborative Nephrotic Syndrome Study
suggests that they tolerate it very well [361. An alternative
therapy, of course, would be dipyridamole in combination with
either aspirin or warfarin (Coumadin). Donadio et al at the
Mayo Clinic reported a one-year controlled trial of dipyrida-
mole and aspirin in adults with this disease [15]. Those receiv-
ing this regimen stablilized their glomerular filtration rates and
normalized their platelet survival. Serial biopsies were not
performed and the effect of the regimen on urinary abnormali-
ties was not reported. Zimmerman and colleagues reported a
one-year controlled trial of dipyridamole and warfarin with
much the same result [14]. Proteinuria diminished and the
progressive deterioration was slowed or halted. As I discussed
previously, several patients in both of these trials had moderate
to severe renal failure at the beginning of treatment; this raises
the question of whether their progressive deterioration was
largely a result of nonimmunologic, as opposed to immunologic,
injury.
As 1 see the pathogenesis of MPGN, the first event is injury
of the glomerular endothelium, which results in the loss of
anionic groups and in increases in its permeability to macromol-
ecules [37]. As a result, nephritogenic material, either immune
complexes or antigen and antibody separately, enters and
produces an inflammatory reaction. This process could be
halted by either eliminating nephritogenic material from the
circulation or reversing the endothelial injury, In acute post-
streptococcal glomerulonephritis and the nephritis of chronic
antigenemia, nephritogenic material leaves the circulation. In
MPGN, the disease becomes chronic because nephritogenic
material persists and the resultant inflammation perpetuates the
endothelial injury. I see the prednisone as perhaps reducing the
amount of nephritogenic material in the circulation but, more
important, I believe it reverses the endothelial injury by an
antiinflammatory effect. Presumably, the latter happens slowly
with long use of prednisone and not when the drug is used in
short intensive courses.
If this concept is correct, it is difficult to see a role for platelet
inhibitor therapy. The products of platelet activation and/or
destruction formed as platelets pass through inflamed, compro-
mised glomerular capillaries are postulated to produce the
mesangial inflammatory reaction [38]. Platelet inhibitor therapy
reduces this inflammatory reaction by normalizing platelet
survival [15]. If platelets played an important role in producing
the glomerulitis by this mechanism, diseases characterized by
severe glomerular inflammation such as acute poststreptococ-
cal nephritis, systemic lupus erythematosus, and the nephritis
of chronic antigenemia would never resolve except by the
inhibition of platelet activation. Because they can and do heal
despite continuing platelet destruction, it is difficult to see how
platelet destruction plays a large role in the chronicity of MPGN
and how platelet inhibitors would be effective against the injury
produced by the immunologic insult.
DR. DAVID BUSHINSKY (Renal Section, Mitchell Hospital):
Patients who have membranoproliferative glomerulonephritis
and who subsequently develop renal failure often undergo renal
transplantation. At the time of transplantation these patients are
given continual therapy with prednisone and other immunosup-
pressive drugs. Yet despite what you might consider optimal
treatment, patients who have had renal transplants often have a
recurrence of their original disease. How do you reconcile this
observation with your recommended treatment? I also would
like to know whether there are any other forms of experimental
therapy currently being evaluated for this disease,
DR. WEST: I can only propose hypotheses to answer your
question. Many years ago I reassured parents that the post-
transplant use of prednisone would prevent MPGN from recur-
ring. I soon found, however, that I was wrong, as attested by
the first patient presented today. I would hazard two explana-
tions. One is that, as I mentioned, glomerular endothelial injury
is critical to the development of the disease. We know the
endothelium is injured in transplant rejection. If the prednisone
were suboptimally effective against this injury, as compared to
the injury 1 postulate to initiate the disease, and if this rejection
injury predisposes to the deposition of nephritogenic material,
and if the patient has nephritogenic material circulating, the
disease could develop despite the use of prednisone. The
second point is that the disease often manifests itself several
years after the transplant, by which time the dose of prednisone
has been lowered to a level adequate to prevent rejection but
possibly inadequate for preventing the development of
glomerulonephritis.
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With respect to experimental therapy, in addition to the
regimens employing dipyridamole that I mentioned, the use of
nonsteroidal antiinflammatory agents is championed by other
groups, particularly in Europe.
DR. SEn&FINo GARELLA (Renal Division, Michael Reese
Hospital, Chicago): Membranoproliferative glomerulonephritis
is known to have a variable clinical course. Spontaneous
changes in degree of hematuria, proteinuria, and renal function
are the rule rather than the exception, even in the absence of
treatment. In view of this, it is possible that your 2 groups of
patients were not comparable. That is, might those treated with
an average delay of 42 months represent a group from which
patients experiencing a spontaneous remission had already
been culled out, leaving only those with more severe and
unremitting disease? Conversely, might those treated with an
average delay of only 12 months represent a group that included
some individuals who were destined to improve spontaneously?
If so, differences in the selection process, rather than in the
effectiveness of treatment, might explain the observed differ-
ence in clinical outcome.
DR. WEST: You have a legitimate criticism of the analysis and
I, too, have worried about the homogeneity of the two groups.
However, a number of points make me feel that the disease in
the two groups was of comparable severity. First, as indicated
by Watson et a! [21], patients who are likely to have mild
disease, spontaneous remissions, and a good prognosis are
those with focal and segmental lesions. The 6 patients we saw
with this morphology [25], all of whom have done very well,
were excluded from our analysis; all those who were included
had diffusely proliferative glomerulitis. Thus, many of those
with a good prognosis have been culled from both groups.
Second, both Habib and colleagues [20] and Cameron and
coworkers [7] have pointed out that patients with nephrotic
syndrome at presentation or who develop it later constitute the
group with the poorest prognosis. You can see from the data
presented in Table 2 that nephrotic syndrome with edema was
somewhat more frequent in the group with the best outcome,
that is, the minimal-delay group. In that group, 24% had edema
at clinical onset versus 20% in the long-delay group. Third, the
rate at which glomerular sclerosis developed was approximate-
ly the same in the two groups. The long-delay group developed
11.4% sclerotic glomeruli over an average of 42 months after
clinical onset, whereas the minimal-delay group developed
13.7% sclerotic glomeruli over an average of 33 months from
clinical onset (Table 5). This difference was not significant but,
if anything, suggests that the group with the best outcome might
have had even more severe disease. Tubular atrophy over the
same period occurred to the same extent in the two groups.
Finally, I should point out that the start of the regimen in
relation to the time of disease onset rather than of clinical onset
would be a more meaningful criterion for dividing up the
patients. It is well known, however, that patients can have
proteinuria for several years before they become symptomatic
and before a diagnosis of MPGN is made [8, 39]. Our minimal-
delay group is probably contaminated with a number of patients
whose disease had remained undiagnosed for more than a year.
This would be especially true of 3 of the 25 in this group
(Patients 9, 16, and 21) who not only presented with levels of
serum creatinine of 1.6 mg/dl or greater but who also have had
persistently elevated levels, suggesting that they had had
asymptomatic disease for a considerable period. Patient 16 had
40% sclerotic glomeruli on the first biopsy; Patient 21 had 12%.
Even though they probably had had their disease for several
years, they were by definition in the minimal-delay group
because the regimen was started shortly after they presented.
They have responded to the regimen less well than did the
others in this group and their elimination from the group would
strengthen the conclusion that the regimen favorably alters the
natural history of the disease, especially if it is initiated soon
after onset. Therefore I do not believe that the method of
analysis of the data is perfect, but I also do not believe that the
imperfections result in erroneous conclusions. I am personally
satisfied after careful scrutiny that the disease in the two groups
was approximately equal in its severity and that without inter-
vention, both would have had the same natural history.
DR. SAMUEL GOTOFF (Chairman of Pediatrics, Michael
Reese Hospital): There are two potential parameters of disease
activity that you haven't mentioned. The first is the immunoflu-
orescent pattern of glomerular deposition. The other, which
admittedly is much more complicated to assess, is the products
of complement consumption. You showed us data for C3, but I
wonder whether you have information about other complement
components, particularly products of complement activation.
DR. WEST: With respect to glomerular immunofluorescence,
we have complete data for nearly all the biopsies but that
information was not helpful in this analysis. For instance, S
patients with type-I MPGN presented with edema, gross hema-
turia, and hypertension. In our experience, patients with this
presentation do very well with the alternate-day regimen. Of the
5, all but one noncompliant patient showed marked improve-
ment, both clinically and in glomerular morphology. However,
even though few deposits could be seen in the ultrastructure of
these biopsies, labeled antibody to C3—particularly to C3dg
(alpha 2D)—produced considerable fluorescence. This and oth-
er experiences lead us to believe that immunofluorescence, as
compared to other modalities, is an imprecise measure of
improvement.
With respect to the perturbation of the complement system, I
have presented data indicating that a low level of C3 has been
disappointing as an indicator of disease activity. The same can
be said for CS. The CS levels are always low, roughly in parallel
with C3 levels in type I and III, but they are normal when the C3
concentration is depressed as the result of circulating C3
nephritic factor (C3NeF), as in patients with type II. To activate
C3, C5 must be removed from the fluid phase by attachment to
several C3b molecules deposited in close proximity on a
surface. The immobilized CS then can be activated by either the
classical or alternative C3 convertase. Apparently this condi-
tion is not met when the hypocomplementemia is the result of
circulating C3NeF.
There is evidence for classical pathway activation in type-I
MPGN. Thus, levels of Cl, C4, and C2 occasionally are low in
the very hypocomplementemic patient in the absence of a
nephrotic syndrome. Parenthetically, a nephrotic syndrome per
se can depress Clq and C2 levels [40]. We have yet to see
evidence of classical pathway activation in type III and have
seen only one patient with type III who possibly had circulating
C3NeF, and that in very low concentration. If the classical
pathway is not involved in type III and C3NeF is not present, it
is difficult to understand the origin of the often-severe hypo-
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complementemia in these patients (Fig, 9). Although the syn-
thetic rate of C3 may be diminished in these patients, contribut-
ing considerably to the low C3 level, clearly C3 is being
activated at the same time because the level of CS is very low,
and products of C3 activation circulate.
With respect to circulating products of complement activa-
tion, a recent study by Dr. Waldo in our laboratory has shown
that Cl inhibitor complexes, (CITNH)2-Clr-Cls, are in normal
concentration in most patients with MPGN but are relatively
abundant during relapse in patients with SLE. The observations
indicate that, relative to SLE, there is little classical pathway
activation in MPGN. There has been, to my knowledge, no
systematic study of C4d levels in MPGN. Piecing together
observations in the literature, one can conclude that in very
hypocomplementemic patients with MPGN, both with and
without C3NeF, the ultimate activation product of C3, C3dg,
would be detectable in the circulation.
DR. COHEN: Do you think C3 nephritic factor has a role in the
pathogenesis of glomerular injury in membranoproliferative
glomerular nephritis?
DR. WEST: I personally think that C3NeF does not have a
role. I believe there is abundant evidence that it is an epiphe-
nomenon and that it is not nephritogenic.
DR. FREDRIC COE (Renal Section, Mitchell Hospital): Are
you now satisfied that no other, controlled studies need to be
done? For example, is a placebo controlled trial now inadvis-
able or inappropriate? Also, would you favor comparing the
alternate-dose prednisone regimen with one of the other regi-
mens that have been discussed, such as an anticoagulant and
antiplatelet agent?
DR. WEST: I personally would be unwilling, with the informa-
tion at hand, to petition an institutional review board to approve
a blind, placebo-controlled study of alternate-day prednisone
therapy in this disease. Moreover, if a review board did approve
such a study, given the information available I don't see how
one could obtain informed consent for participation in the study
from parents or the patients. In view of the favorable, albeit
inconclusive, results of the controlled trials of dipyridamole in
adults 114, 151, I do believe that consideration could be given to
a trial comparing the dipyridamole-aspirin regimen with the
alternate-day prednisone regimen, and obviously one ethically
could compare the alternate-day regimen alone with one com-
bining dipyridamole-aspirin with the alternate-day regimen. The
latter, however, might not provide useful conclusions. A very
important factor in favor of the dipyridamole-aspirin regimen is
that it would not stunt growth. Such a study would be difficult
to conduct because the dipyridamole must be given every 6 or 8
hours, and we have had difficulty with compliance even when
medication is scheduled to be given every 48 hours. Many of the
patients with this disease have no symptoms and have never
been sick; in this setting, compliance can be a problem,
particularly in teenagers. Our observations indicate that aspirin
combined with dipyridamole, which is given once a day in a
dose of 75 to 100 mg, is completely ineffective; in some patients
this regimen might even be harmful (Patients 31 and 33, Fig. 3).
DR. COHEN: To continue in the same vein, one of the
arguments supporting your contention that alternate-day ste-
roid treatment is beneficial is your retrospective comparison
with the untreated patients reported by Habib et al [20]. Yet, if I
understand your comments correctly, some of the patients in
your series who did not receive the strict regimen also appeared
to do better than did the untreated patients in the Habib study.
Thus we have to ask whether the Cincinnati patients with
membranoproliferative glomerulonephritis had the same dis-
ease as did the French patients with membranoproliferative
glomerulonephritis.
DR. WEST: Your point is commonly raised and justifiably so.
Arc there places in the world where MPGN is a mild disease?
One is entitled to ask whether Cincinnati is one of these places.
Additionally, one could ask whether we have any patients
untreated or treated by a different modality who could
be compared with the patients receiving the alternate day
regimen.
In partial answer to these questions I can say that our results
compare favorably not only with those of Habib et al [20] but
also with those from a number of centers. Thus, by the eleventh
year after clinical onset, the actuarial survival of the 105
unselected patients in the Habib series was 41% [20]. Survival
was 48% after 11 years in 45 unselected English children
reported by Cameron and colleagues [7] and was 30% or less in
two series containing a total of 53 children from Canada [21,
22]; the latter were selected because they had diffuse prolifera-
tive disease, as in our study. in contrast, survival after 11 years
in our study was 74%. in the 25 starting the regimen promptly,
survival was 90%; if the noncompliant patient were eliminated
from this group, survival would have been 96% at 11 years.
Our early experience makes us feel that the disease in
Cincinnati is as severe as that in other parts of the world. To
complete the record, we have followed 64 patients with MPGN
at the Children's Hospital Medical Center from January 1957 to
October 1983. The 13 patients who presented between Janury
1957 and the beginning date of the present study, January 1966,
provided data leading to the initial description of the disease
and its relationship to hypocomplementemia [39, 41, 42]. Nine
of these developed end-stage renal disease and are now de-
ceased or have received transplants. Some of these patients
received the alternate-day regimen or a small single daily dose
of prednisone for a relatively short time, but they developed
end-stage renal disease after prednisone was discontinued.
Patients 1 and 2, whose case summaries are given here, are in
this group. The remaining 4 had the same variety of immuno-
suppressive regimens, but the alternate-day regimen that fol-
lowed was not discontinued. All are living with normal or nearly
normal renal function 21 to 23 years after clinical onset. These
patients are not included in the present analysis because of the
variety of immunosuppressive regimens they were given before
the alternate-day regimen was started. Thus, of these 13, the 9
who did not receive the alternate-day regimen or who received
it for only a short time all have developed end-stage renal
disease, as would be predicted from the experience of Habib et
al [20], Cameron et at [7], Watson et al [21], and Magil et al [22].
Finally, in answering this comment, I can refer you to the
data presented in Table I comparing the patients of Habib with
those of our study. As I mentioned, both Habib [20] and
Cameron [7], after experience with many patients, state that a
nephrotic syndrome at presentation or later bodes a poor
prognosis. In our series, 47% had a nephrotic syndrome,
whereas 67% of Habib's and 33% of Cameron's patients pre-
sented in this way. Habib et al also pointed out the ominous
prognosis associated with epithelial crescents in the first biop-
Childhood MPGN 1091
sy; 94% of her 16 patients with crescents developed end-stage
renal disease. We had exactly the same percentage of patients
with crescents as in her series, 15%; of these, only one (14%)
developed end-stage renal disease. From these data, it is
difficult for us to conclude that the basic disease in our locality
is less severe than that elsewhere.
Dg. GARY TOBACK (Renal Section, Mitchell Hospital): One
of the problems in analyzing membranoproliferative glomerulo-
nephritis is that three different morphologic entities are lumped
together under the same name. Is it worth considering nonmor-
phologic parameters in an attempt to determine whether more
than one disease is under study? For example, are there
differences among the three morphologic types with regard to:
(1) the plasma concentration of different classes of immunoglob-
ulins, (2) B- and T-cell function, or (3) the different responses of
young children and adults to treatment?
DR. WEST: Our laboratory is interested in the clinical and
laboratory correlates among the three types of MPGN. First, I
should note that many people are lumpers and consider type III
as only a variant of type I and not a distinct entity. The two
types do share many aspects of pathogenesis. It has been shown
by others [43, 44] that segments of the short arm of chromo-
some 6 may be unique in that they exhibit crossover suppres-
sion during meiosis. With crossover suppression, the segments
containing genes for HLA-B and -DR, for four of the comple-
ment components, and for the red cell enzyme glyoxalase, are
passed intact to progeny. About one-quarter of the 6th chromo-
somes contain these "extended haplotypes." A specific extend-
ed haplotype has been found by Welch in our laboratory to be
present in 29% of patients with types-I and -III MPGN and in
only 2% of normal individuals. This finding suggests that a gene
or genes on this segment predispose to both of these types.
Likewise, inherited deficiencies of complement components are
significantly more frequent in both types I and III than in
normal subjects [45]. Further, we have a family in which one
child has type I and another has type III [461. Despite this
evidence of a similar basic pathogenesis, we find that evidence
for classical pathway activation, seen in a few patients with
type I, is not present in type III. Also, patients with type I
present with symptoms of glomerulonephntis, systemic illness,
or both with significantly greater frequency than do those with
type III. Significantly more patients with type III present as
healthy children with chance proteinuria (P < 0.01). Thus there
is evidence on clinical as well as on morphologic grounds that
type-Ill MPGN is distinct from type-I, but the two types appear
to have common genetic factors in their pathogenesis.
I know of no difference in the classes of immunoglobulins or
the subclasses of IgG. Obviously, IgG is frequently in low
concentration in all three types because of a nephrotic syn-
drome. T-suppressor cells have been reported to be low in
patients with type I as compared to normal subjects, but data
are not available on this point for type III [47]. With respect to
response to treatment, it is our impression that type III is more
resistant than is type I. This is hard to prove. I believe our
impression arises from the fact that, as I mentioned, we have
seen signs of disease in 5 patients with type I who were severely
ill initially but who had complete clinical resolution and virtual-
ly complete normalization of glomerular morphology. Such a
response was never observed in the type-Ill patients in our
study, even though they often presented as healthy children
with chance proteinuria.
DR. COHEN: In what percentage of patients with MPGN are
circulating immune complexes found? Do the levels of circulat-
ing complexes change in response to therapy, and do they
correlate with the course of the disease?
DR. WEST: When we systematically measured circulating
immune complexes (CIC) a number of years ago [41, using the
solid-phase Clq method, we were disappointed with the correla-
tions. Although CIC are demonstrable in abnormally high
concentrations in many patients with all three types, the
concentrations were rarely as high as those in active systemic
lupus erythematosus. Paradoxically, the levels were the highest
in patients in whom the disease seemed to be of recent onset
and in those with a mild form, and were rare in those with long-
standing disease and in whom function was somewhat compro-
mised. With the alterate-day regimen, the levels fell. Some
patients who lost their hypocomplementemia and urinary ab-
normalities, however, continued to have elevated levels of dC.
This finding suggests that the CIC we were measuring were not
nephritogenic. Their levels showed no correlation with C3
levels. In general, the measurements were of little prognostic
value and were not helpful to us in following patients' responses
to the alternate-day regimen.
DR. VIKAS SUKHATME (Renal Section, Mitchell Hospital):
Given the relatively high dose of alternate-day steroids required
and the long duration of treatment, have you considered as an
alternative the use of cyclosporine to minimize the steroid-
related side effects?
DR. WEST: Cyclosporine would be worthy of trial, of course,
if there were reason to believe that it would turn off production
of an antibody critical to the formation of nephritogenic materi-
al. We know, however, that short, intensive courses of cyclos-
phosphamide or azathioprine are of no value, and one would
predict from this knowledge that cyclosporine would have to be
given over long periods it it were to be effective.
DR. GARELLA: I wish to reconsider the statement you made
earlier, that is, that you now believe it is unnecessary to
perform a controlled study of alternate-day steroid therapy in
patients with MPGN. As a nephrologist who must make treat-
ment decisions relating to patients with membranoproliferative
glomerulonephritis, I think we should explore this statement
further by considering more explicitly the potential risks and
benefits of the treatment protocol that you propose. Alternate-
day steroid therapy, which you suggest might be necessary for
the remainder of a given patient's life, has a number of potential
side effects, of which you have outlined at least one, namely
growth retardation. Other side effects also can occur, as is
apparent from today's case presentations.
Are we certain that the benefits to be derived from treatment
outweigh the risks? You maintain that treatment is warranted
by your observations that patients treated within about one year
of appearance of the disease seem to do better than do those
treated after an average delay of 42 months. I already have
commented on the possibility that these two groups might not
be comparable. Other considerations throw some doubt on the
efficacy of treatment. The observation that the disease can
recur in patients who have received transplants, despite ongo-
ing immunosuppressive therapy, is one. The fact that no
differences were observed in the rates at which serum creati-
nine changed between the two groups of patients, at least for
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the first 3 years of observation, is another. This must imply
that, at least from the viewpoint of renal function, disease
progression was not modified by treatment. Finally, you stated
that the two groups of patients were comparable because, at the
beginning of treatment, they had comparable degrees of pro-
teinuria and levels of serum creatinine. I believe, however, that
in this disease the mode of presentation has very little to do with
the long-term course: some patients who present with hyperten-
sion, hematuria, and renal failure can improve and do quite
well; in others, despite a milder initial presentation, the disease
progresses relentlessly. You have shown that hypocomplemen-
temia also does not correlate with the course of the disease.
Therefore, 1 believe that treatment has not yet been proven
effective and that a controlled study ought to be performed.
Because you are a well-known authority in this field, let me also
add that your statement that a controlled study is no longer
needed could be used, in a medical-legal context, as evidence
that immunosuppressive treatment is the "accepted" approach
to this disease. On the contrary; for the reasons I have outlined,
I think a strong case can be made for performing a well-
designed controlled study. I believe it would be justifiable
ethically and scientifically, and I don't think there would he a
problem in obtaining proper informed consent from patients.
DR. WEST: Your comments require me to reiterate the
answers to the queries from several others. I can provide no
definitive reasons for recurrence of disease in the renal trans-
plant but have pointed out that the glomeruli in the transplant
are not as healthy as glomeruli in the natural host and; hence, in
the person with circulating nephritogenic material, the glomeru-
Ii may be more susceptible to nephritic injury. I also have
commented on the two phases of the disease after the start of
the alternate-day regimen. If the patient weathers the first phase
without losing too many glomeruli, there is an excellent chance
that the ravages of the disease as well as dialysis and transplan-
tation can be avoided. I believe it is doubtful that any regimen
would avoid the first phase of glomerular attrition. This disease
produces profound glomerular inflammation; some glomeruli
that appear to be functional are actually so severely damaged
that sclerosis is inevitable.
I believe the four points I made concerning the comparability
of the less-than and the greater-than-one-year delay groups puts
the burden of proof on those who say that the groups differ in
severity of disease. Preoccupation with differences between
these two groups obscures the lesson that can be learned from
the 25 patients who were promptly started on the regimen.
There was nothing biased about their selection except that
those with a good prognosis were eliminated. Some of the 25
were symptomatic; others were asymptomatic on presentation.
These patients can be compared directly with those reported by
Habib et al [201 because their 105 patients were followed for a
period of 5 9/12 years versus 5 11/12 years for our 25 patients.
Their range of followup was one to 18 years; ours was 0.5 to
14,75 years. Over this period, 34 of their 105 patients (32%) died
or were placed on dialysis, whereas only 2 of our 25 (8%)
developed end-stage renal disease (x2 = 5.99, P C 0.02).
Cameron et al [7] had an experience similar to that of Habib et
al; in their series, 16 of 45 children less than 15 years of age
(35%) developed end-stage renal disease over approximately
the same time period. These comparisons make it difficult to
refute the value of the regimen, especially if it is started
promptly after clinical onset. I would point out again that one of
the 2 patients in this group of 25 who developed end-stage renal
disease was noncompliant.
I have commented extensively on what 1 believe to be the
benefits of the treatment and have neglected discussing in detail
the side effects. The regimen has not been intensive enough to
produce aseptic necrosis of bone or osteoporosis. In a few
patients, it has produced cataracts, but their frequency is less
than in our posttransplant patients, and in none have the lesions
interfered with vision. Growth retardation in children under the
age of 14 years has been the most serious consequence of the
regimen. It is a complication that is difficult for the child to face,
and it is the one side effect that should keep us looking for a
better way to manage this disease. At present, however,
balancing the benefits against the risks, my colleagues and I
believe that an intelligent patient or parent, fully informed by a
physician of the experience detailed in this study, would not
consent to a blind, placebo-controlled trial, especially if the
patient had disease of recent clinical onset.
Reprint requests to Dr. C. West, Division of Nephrology, Children's
Hospital Medical Center, Bland and Bethesda Avenues, Cincinnati,
Ohio 45229, USA
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